Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Imaging Diagnostic Systems , Inc. announced that it has hired Dr. Rajesh Suresh Sheth as the Company’s Managing Director for India.

Imaging Diagnostic Systems , Inc., (OTCBB:IMDS) announced that it has hired Dr. Rajesh Suresh Sheth as the Company’s Managing Director for India. Dr. Sheth will be responsible for marketing and promoting the CT Laser Mammography system to hospitals and imaging centers throughout Mumbai and New Delhi.

“I personally feel that this modality, i.e. CTLM will facilitate quality healthcare & provide one of the best health care solution for a diagnostic approach in Mammography,” commented Dr. Rajesh Sheth, Chief Radiologist of Shree Krishna Polyclinic.

Dr. Rajesh Sheth has been in the field of radiology, with more than 18 years of experience and is regarded as an establish leader in his field. He served as Chief of Radiology in various hospitals throughout his career and is currently involved in establishing mammography centers in cities with smaller populations in an effort to increase the awareness of breast cancer in these areas.

“We are pleased to have Dr. Sheth as an advocate for the CTLM system,” stated Deborah O’Brien, IDSI’s Senior Vice President. “His desire to increase breast cancer awareness is admirable and we are looking forward to collaborating with him.”

About Imaging Diagnostic Systems , Inc.

Imaging Diagnostic Systems , Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a patented new breast imaging system that utilizes continuous wave laser technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit corporate website: www.imds.com

Source: Imaging Diagnostic Systems , Inc.